T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2B |
| 2 |
Sea Limited
SE
|
+$1.34B |
| 3 |
Morgan Stanley
MS
|
+$1.23B |
| 4 |
Incyte
INCY
|
+$1.05B |
| 5 |
Ross Stores
ROST
|
+$968M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.05B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.5B |
| 3 |
Visa
V
|
+$1.16B |
| 4 |
JPMorgan Chase
JPM
|
+$1.13B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.01% |
| 2 | Healthcare | 17.6% |
| 3 | Consumer Discretionary | 14.37% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 10.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Chegg
CHGG
$89.3M
| $9.55M | ﹤0.01% |
142,056
-20,416
| -13% | -$1.09M |
|
|
ESPR
1302
DELISTED
Esperion Therapeutics
ESPR
| $9.51M | ﹤0.01% |
185,327
-15,515
| -8% | -$649K |
|
1303
Puma Biotechnology
PBYI
$450M
| $9.44M | ﹤0.01% |
905,357
-130,254
| -13% | -$1.35M |
|
|
PBCT
1304
DELISTED
People's United Financial Inc
PBCT
| $9.42M | ﹤0.01% |
814,344
-62,217
| -7% | -$724K |
|
1305
Markel Group
MKL
$22.8B
| $9.34M | ﹤0.01% |
10,117
-164
| -2% | -$149K |
|
1306
Stoke Therapeutics
STOK
$2.02B
| $9.33M | ﹤0.01% |
391,358
-36,164
| -8% | -$859K |
|
1307
Leggett & Platt
LEG
$1.29B
| $9.16M | ﹤0.01% |
260,660
-9,363
| -3% | -$290K |
|
|
AMK
1308
DELISTED
AssetMark Financial Holdings, Inc.
AMK
| $9.13M | ﹤0.01% |
334,582
-33,515
| -9% | -$821K |
|
1309
FRP Holdings
FRPH
$425M
| $9.04M | ﹤0.01% |
445,802
+470
| +0.1% | +$9.73K |
|
1310
OneSpaWorld
OSW
$2.73B
| $8.91M | ﹤0.01% |
1,867,798
-1,333,264
| -42% | -$7.24M |
|
|
EXPR
1311
DELISTED
Express, Inc.
EXPR
| $8.88M | ﹤0.01% |
288,350
+43,430
| +18% | +$1.6M |
|
1312
Invitation Homes
INVH
$17.7B
| $8.83M | ﹤0.01% |
320,697
-49,128
| -13% | -$1.23M |
|
1313
Axalta
AXTA
$7.93B
| $8.8M | ﹤0.01% |
390,408
-44,251
| -10% | -$905K |
|
1314
Ambev
ABEV
$43.5B
| $8.66M | ﹤0.01% |
3,280,700
-599,000
| -15% | -$1.41M |
|
1315
NOV
NOV
$7.45B
| $8.61M | ﹤0.01% |
702,668
-69,215
| -9% | -$851K |
|
1316
Orion
OEC
$364M
| $8.59M | ﹤0.01% |
811,134
+245,308
| +43% | +$2.27M |
|
1317
Utz Brands
UTZ
$1.25B
| $8.49M | ﹤0.01% |
+619,543
| New | +$7.18M |
|
|
MRO
1318
DELISTED
Marathon Oil Corporation
MRO
| $8.46M | ﹤0.01% |
1,382,979
-181,664
| -12% | -$1M |
|
|
LDL
1319
DELISTED
Lydall, Inc.
LDL
| $8.46M | ﹤0.01% |
623,996
-6,048
| -1% | -$66.9K |
|
1320
STRATTEC Security
STRT
$338M
| $8.4M | ﹤0.01% |
526,981
+13,433
| +3% | +$205K |
|
|
NBL
1321
DELISTED
Noble Energy, Inc.
NBL
| $8.29M | ﹤0.01% |
925,811
-23,902
| -3% | -$214K |
|
|
CNST
1322
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $8.23M | ﹤0.01% |
274,039
-253,828
| -48% | -$9.14M |
|
1323
Globant
GLOB
$1.77B
| $8.22M | ﹤0.01% |
54,876
-4,234
| -7% | -$523K |
|
1324
The Mosaic Company
MOS
$6.92B
| $8.17M | ﹤0.01% |
653,349
-35,726
| -5% | -$428K |
|
1325
Trade Desk
TTD
$6.84B
| $8.17M | ﹤0.01% |
201,050
-5,230
| -3% | -$158K |
|
Similar funds
T. Rowe Price Associates's Q2 2020 Portfolio in Review
As of Q2 2020, T. Rowe Price Associates held 2,591 positions worth $795B, up 26% from $632B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
T. Rowe Price Associates's Q2 2020 filing shows 79 new, 1,096 increased, 1,255 reduced and 100 closed positions. Its largest new stake was Vroom Inc: 200,362 shares worth $797M. The largest sale was Boeing, an estimated $2.05B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2020 buy was Vroom Inc: 200,362 shares worth $797M.
- T. Rowe Price Associates added most to Microsoft in Q2 2020, an estimated $2B increase.
- T. Rowe Price Associates's biggest Q2 2020 reduction was Boeing, cutting an estimated $2.05B.
- T. Rowe Price Associates fully exited Raytheon Company in Q2 2020, selling an estimated $1.01B.
- T. Rowe Price Associates's ten largest holdings make up 25% of its $795B portfolio in Q2 2020.
- T. Rowe Price Associates opened 79 new positions and closed 100 in Q2 2020.
- T. Rowe Price Associates's portfolio value rose 26% quarter-over-quarter to $795B.
Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.